Company: INMB
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001213900-25-073077
Chunk: 38

Company: Inmune Bio, Inc.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 38
---
 on equity and debt financing to fund
its operations.

Other Developments

The new U.S. administration
has announced or imposed a series of tariffs on U.S. trading partners. In response, several countries have threatened or imposed retaliatory
measures. At this time, we do not anticipate the tariffs and changes in trade policies in place as of the filing of this Quarterly Report
on Form 10-Q to have a significant adverse effect on our business or operations.

Following recent changes more
broadly within the NIH and FDA, we have not noticed any disruption of communications with the NIH and FDA to date and continue to maintain
productive interactions. To date, there has been no impact to the Company’s operations due to any changes at the NIH or FDA.

Research and Development

Research and development expense
consists of expenses incurred while performing research and development activities to discover and develop our product candidates. This
includes conducting preclinical studies and clinical trials, manufacturing development efforts and activities related to regulatory filings
for product candidates. We recognize research and development expenses as they are incurred. Our research and development expense primarily
consist of:

●clinical
trial and regulatory-related costs;

28

    ●
    expenses incurred under agreements with investigative sites and consultants that conduct our clinical trials;

    ●
    manufacturing and testing costs and related supplies and materials; and

    ●
    employee-related expenses, including salaries, benefits, travel and stock-based compensation.

The following table summarizes
our research and development expenses by product candidate for the periods indicated (in thousands):

    Three Months Ended  
    Six Months Ended 

    June 30,  
    June 30, 

    2025  
    2024  
    2025  
    2024 
  
    External Costs 

    DN-TNF - Alzheimer’s disease 
    $3,249  
    $4,776  
    $8,101  
    $11,130 
  
    INKmune - High Risk MDS/AML & Prostate cancer and CORDStrom 
     1,092  
     1,067  
     2,365  
     2,254 
  
    Preclinical and other programs 
     62  
     248  
     62  
     361 
  
    Accrued research and development rebate 
     (243) 
     (953) 
     (336)